Literature DB >> 25511151

Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population.

Philip E Castle1, Katherine M Smith2, Thomas E Davis3, Kathleen M Schmeler4, Daron G Ferris5, Ashlyn H Savage6, Jermaine E Gray7, Mark H Stoler8, Thomas C Wright9, Alex Ferenczy10, Mark H Einstein11.   

Abstract

OBJECTIVES: The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform.
METHODS: In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA).
RESULTS: The κ and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5%, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0% using specimen A and 90.4% using specimen B for Xpert, 90.4% for cobas, and 81.6% for hc2.
CONCLUSIONS: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Microbiology; Molecular diagnostics; Virology

Mesh:

Year:  2015        PMID: 25511151     DOI: 10.1309/AJCP4Q0NSDHWIZGU

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

1.  Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon.

Authors:  Adebola Adedimeji; Rogers Ajeh; Anastase Dzudie; Ernestine Kendowo; Norbert Fuhngwa; Denis Nsame; Andre Gaetan Simo-Wambo; Enow Orock; Tiffany M Hebert; Amanda J Pierz; Daniel Murokora; Kathryn Anastos; Philip E Castle
Journal:  J Clin Virol       Date:  2020-05-19       Impact factor: 3.168

Review 2.  Advances in technologies for cervical cancer detection in low-resource settings.

Authors:  Kathryn A Kundrod; Chelsey A Smith; Brady Hunt; Richard A Schwarz; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Expert Rev Mol Diagn       Date:  2019-08-01       Impact factor: 5.225

3.  Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).

Authors:  Kate Cuschieri; Daan Geraets; Jack Cuzick; Louise Cadman; Catherine Moore; Davy Vanden Broeck; Elisaveta Padalko; Wim Quint; Marc Arbyn
Journal:  J Clin Microbiol       Date:  2016-07-06       Impact factor: 5.948

4.  A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282.

Authors:  Timothy Wilkin; Huichao Chen; Vikrant Sahasrabuddhe; Roy Matining; Rosie Mngqibisa; Lameck Chinula; Yamikani Mbilizi; Tsitsi Magure; Ayotunde E Omoz-Oarhe; Mohammed Rassool; Cynthia Riviere; Rhamesh Bhosale; Sheela Godbole; Reena Naranjo; Robert Coombs; Pamela Michelow; Catherine Godfrey; Cynthia Firnhaber
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

Review 5.  HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Authors:  F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

6.  Field Evaluation of Xpert HPV Point-of-Care Test for Detection of Human Papillomavirus Infection by Use of Self-Collected Vaginal and Clinician-Collected Cervical Specimens.

Authors:  P Toliman; S G Badman; J Gabuzzi; S Silim; L Forereme; A Kumbia; B Kombuk; Z Kombati; J Allan; G Munnull; C Ryan; L M Vallely; A Kelly-Hanku; H Wand; G D L Mola; R Guy; P Siba; J M Kaldor; S N Tabrizi; A J Vallely
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948

7.  Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV.

Authors:  Grant B Ellsworth; Elizabeth A Stier; Elizabeth Y Chiao; Shelly Y Lensing; Teresa Darragh; Naomi Jay; J Michael Berry-Lawhorn; Mark Einstein; Luis F Barroso; Ross D Cranston; Rebecca Levine; Humberto M Guiot; Audrey L French; Stephen E Goldstone; Wolfgang Preiser; Mathilda Claassen; Joel M Palefsky; Timothy J Wilkin
Journal:  J Acquir Immune Defic Syndr       Date:  2021-07-01       Impact factor: 3.771

8.  Attitude to Human Papillomavirus Deoxyribonucleic Acid-Based Cervical Cancer Screening in Antenatal Care in Nigeria: A Qualitative Study.

Authors:  Temitope E Filade; Eileen O Dareng; Toyosi Olawande; Tolani A Fagbohun; Amos O Adebayo; Clement A Adebamowo
Journal:  Front Public Health       Date:  2017-09-06

9.  Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women.

Authors:  Zizipho Z A Mbulawa; Timothy Wilkin; Bridgette J Goeieman; Eefje Jong; Pamela Michelow; Avril Swarts; Jennifer S Smith; Patricia Kegorilwe; Cynthia S Firnhaber; Anna-Lise Williamson
Journal:  Am J Clin Pathol       Date:  2017-08-01       Impact factor: 2.493

10.  A simple and rapid diagnostic method for 13 types of high-risk human papillomavirus (HR-HPV) detection using CRISPR-Cas12a technology.

Authors:  Jiaojiao Gong; Guanghui Zhang; Wangguo Wang; Liping Liang; Qianyun Li; Menghao Liu; Liang Xue; Guanghui Tang
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.